Biogen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +45

Biogen Inc. stock holds near 12 month high on steady Q1 2026 growth

AI-generated analysis

📈 Biogen Inc. stock is trading near its 12-month high of $225.80, currently at an opening price of $220.83 on September 5, 2026.

💰 The company reported Q1 2026 revenue of $2.5 billion, marking a stable 1.9% increase compared to the same quarter last year.

📊 Over the trailing twelve months through Q1 2026, Biogen's total revenue reached $9.9 billion, highlighting its operational scale.

🎯 Analysts maintain a 'Moderate Buy' consensus with an average price target of $228.50, indicating limited immediate upside from current levels.

🧬 Biogen focuses on neurology and rare diseases, including therapies for multiple sclerosis and other central nervous system disorders.

🏆 Historically, the company has demonstrated the ability to beat earnings consensus, such as delivering $3.60 EPS versus a $2.94 consensus in a prior period.

🤝 Institutional investors like B. Metzler seel. Sohn & Co. AG actively manage positions in Biogen Inc.

Bullish Signals
  • Biogen Inc. stock is trading near its 12-month high of $225.80, indicating strong investor confidence and a recovery from the 12-month low of $135.39.
  • The company achieved stable revenue growth in Q1 2026 with a 1.9% year-over-year increase to $2.5 billion, signaling resilience in its core business.
  • Biogen has a history of beating earnings consensus expectations, having previously delivered $3.60 per share versus a $2.94 analyst consensus.
Risk Factors
  • The current stock price of $220.83 is only a few dollars below the average analyst target of $228.50, suggesting that much of the expected upside is already priced in.
  • Q1 2026 revenue growth of 1.9% is described as 'not explosive,' which may limit the ability to justify pushing the stock significantly higher without new catalysts.
Full Analysis
Biogen Inc. (BIIB) shares are trading near their 12-month high of $225.80, currently opening at $220.83 on the NASDAQ as of September 5, 2026. The stock is approaching its average analyst price target of $228.50, suggesting that much of the expected upside may already be priced in. Investors are closely watching the company's performance against a backdrop of strong peer activity, such as Ipsen's reported growth. The company reported Q1 2026 revenue of $2.5 billion, representing a modest but stable increase of 1.9% year-over-year. Over the trailing twelve months ending in Q1 2026, Biogen's total revenue reached $9.9 billion. While this growth is not explosive, it signals stability in the company's core business at the start of its 2026 financial year. Biogen focuses primarily on neurology and rare diseases, with a pipeline that includes therapies for multiple sclerosis and other central nervous system disorders. The market expects the company to defend and expand its franchise as competition intensifies and payers scrutinize costs. Future stock performance will likely depend on fresh evidence of stronger growth or significant progress from new therapies rolling through the pipeline.